Deacon's Challenge

No 94 - Answer

Serum AFP levels are being monitored following curative surgery for hepatoblastoma in a two-year old boy. Samples are normally being taken at veekly intervals but a repeat sample is taken in error two days after the routine week of sample. The requesting clinician is concerned that thi sample appears to show evidence of disease recurrence. Assuming a biological variation of 12% and an analytical CV of 6% for this assay, determine whether this concern is justified.

Day 7 14 21 28 30 AFP (kIU/L) 1,613,000 723,000 329,000

FRCPath. Autumn 2008

If there had been no recurrence of the tumour then we would expect the AFP to continue to fall after 28 days as it continues to be cleared from the circulation. However, the value at 30 days has risen slightly. So the problem is to decide whether this value is significantly different from the expected concentration taking into account both the biological and analytical imprecision.

The first step is to estimate the expected AFP concentration at 30 days. The clearance of a tumour marker such as AFP normally follows first-order kinetics and the linear form of the

$$\ln Cp_{\dot{t}} = \ln Cp_{\dot{0}} \cdot k_{\dot{d}} \cdot t$$

Where $\ln Cp_t$ and $\ln Cp_0$ are the natural logarithms (to the base 2.718, usually denoted as \log_e or \ln) of the plasma concentrations at times t and zero respectively. k_d is the elimination rate

A useful first step is to calculate In for each concentration and to plot the values against to



ACB News | Issue 550 | February 2009

Practice FRCPath Style Calculations | 13

The data points for 7, 14, 21 and 28 days all fall on a straight line confirming that the clearance of AFF follows first order kinetics. Furthermore the value at day 30 is above the line suggesting that there may well be a recurrence of the tumour. By extrapolating the line beyond 28 days it is possible to read off the expected in AFP value at 30 days as 11.66. Taking the antilog then gives a concentration of 116,000 kUIV. Cut 3 sig figs).

A concentration of 11-6,000 km. (to 3.9 g) methods the fixed point of treetly from the data. Using any two data points the value of the elimination rate constant $(k_0^2$ can be calculated then used to obtain the expected concentration at 30 days. Alternatively, if the day 7 result is taken as the initial value $(n_i C_{p_i})$, the mean of the results for days 14, 21 and 28 as $(n_i C_{p_i})$ and the mean value of $(n_i C_{p_i})$, the mean of the results for days 14, 21 and 28 as $(n_i C_{p_i})$ and the mean value of $(n_i C_{p_i})$ the mean value of $(n_i C_{p_i})$ the mean value of $(n_i C_{p_i})$ the mean $(n_i C_{p_i})$ the $(n_i C_{p_i})$ the mean $(n_i C_{p_i})$ the $(n_i C_{p_i})$ the $(n_i C_{p_i})$ the mean $(n_i C_{p_i})$ the $(n_i C_{p_i})$

```
ln Cp_0 = 14.29
  lnCp_t = 13.49 + 12.70 + 11.88 = 12.69
     t = (14-7) + (21-7) + (28-7) = 7 + 14 + 21 = 14 days
Substitute these values and solve for kd:
```

12.69 =
$$14.29 - kd.14$$

 $kd = \frac{14.29 - 12.69}{14} = 0.114 \text{ days}^{-1}$

Substitution of this value for k_d , the $\ln Cp_0$ result and t corresponding to 30 days (30 – 7 = 23 days) into the rate equation allows calculation of the expected $Cp_{\hat{t}}$

$$\ln Cp_t = 14.29 - (0.114 \times 23) = 14.29 - 2.62 = 11.67$$

 $Cp_t = \text{antilog } 11.67 = 117,000 \text{ kIU/L}$

which is very close to the graphically determined concentration.

The next step is to calculate the total imprecision at this concentration. The combined CV (CV_{Total}) of this AFP result can be calculated from the expression:

Therefore the 95% confidence limits at the expected concentration of 117,000klU/L (mean $\pm 1.965D$) are:

Issue 550 | February 2009 | ACB News

117,000 - (1.96 x 15,700) to 117,000 + (1.96 x 15,700)

= 117,000 - 30,800 to 117,000 + 30,800 (3 sig figs)

= 86,200 kIU/L to 147,800 kIU/L

The measured value at 30 days (149,000 kIU/L) is just outside of these limits indicating that the clinician's fear of a possible recurrence is justified. The value obtained at the next sampling time (35 days) should clarify.

Ouestion 95

Reproduced below are peak area data from an HPLC analytical run set up to measure plasma phenylalanine. The assay is used to monitor adequacy of dietary control in patients with phenyliketouria, good control being regarded as maintaining plasma phenylalanine between 120 and 360 µmol/L. Whenthyl phenylalanine has been used as the internal standard, 200 µL of internal standard has been added to 200 µL aliquots of samples and standards prior to analysis.

Standard concentration = 500 µmol/L N-methyl phenylalanine (NMP) concentration = 100 µmol/L QC target: 180 – 210 µmol/L

I am a Clinical Biochemistry Registrar in Sydney, Australia. Earlier this year I was required to sit a paper of calculations and found the Deacon's Challenge series of problems invaluable in my preparation. However, I believe there is a simple and obvious flaw in the answers to challenge No 84 (March 2008) and a similar problem, No 47 (Feb 2005).

a similar prolem, No 47 (Peb 2005).

The problem pertain to the question of determining whether a particular concentration of protein in the CVF deliver from C

Dr Amanda Caswell Pacific Laboratory Medicine Services, Royal North Shore Hospital Sydney, Australia